1. RECOVERY. Open label(No blinding). Evidence dexamethasone + . HCQ arm-(press release, pre-prints 2 week later)
3. Lopinavir/Ritonavir for Severe COVID. No Blinding.(responsible for dropping Lopinavir/Ritonavir from Indian guidelines in march)
6. DISCOVERY trial (ongoing.open label)
So since we don't have perfect "trials" .how should we look at Evidence
2. For soft end points (symptoms , radiology). V. Difficult.
3. Reputation of Trial group(NIH,NHS).Did they follow due process (adjusted interim analysis etc n announced regularly)